# Arun Rajan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/arun-rajan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,623 |
| Field | Myasthenia Gravis and Thymoma |
| h-index | 46 |
| i10-index | 96 |
| Last Known Institution | National Institutes of Health |
| OpenAlex ID | https://openalex.org/A5083000419 |
| ORCID iD | 0000-0003-2776-3385 |
| Works | 265 |

## Researcher papers

- [The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?](https://scholariq.org/papers/the-2021-who-classification-of-tumors-of-the-thymus-and-mediastinum-what-is-new/)
- [Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial](https://scholariq.org/papers/sunitinib-in-patients-with-chemotherapy-refractory-thymoma-and-thymic-carcinoma/)
- [Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial](https://scholariq.org/papers/avelumab-for-metastatic-or-locally-advanced-previously-treated-solid-tumours/)
- [Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial](https://scholariq.org/papers/avelumab-for-patients-with-previously-treated-metastatic-or-recurrent-non-small/)
- [Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial](https://scholariq.org/papers/molecular-profiling-and-targeted-therapy-for-advanced-thoracic-malignancies-a/)
- [Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors](https://scholariq.org/papers/phase-ii-study-of-belinostat-in-patients-with-recurrent-or-refractory-advanced/)
- [Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer](https://scholariq.org/papers/clonal-evolution-and-heterogeneity-of-osimertinib-acquired-resistance-mechanisms/)
- [Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy](https://scholariq.org/papers/sicca-syndrome-associated-with-immune-checkpoint-inhibitor-therapy/)
- [Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors](https://scholariq.org/papers/phase-i-study-of-atr-inhibitor-m6620-in-combination-with-topotecan-in-patients/)
- [Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.](https://scholariq.org/papers/local-ablative-therapy-lat-for-oligoprogressive-egfr-mutant-non-small-cell-lung/)

## Researcher topics

- [Myasthenia Gravis and Thymoma](https://scholariq.org/topics/myasthenia-gravis-and-thymoma/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Pituitary Gland Disorders and Treatments](https://scholariq.org/topics/pituitary-gland-disorders-and-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [National Institutes of Health](https://scholariq.org/institutions/national-institutes-of-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.